Payment overview · 2025
General Payments
$588.99
17 reported records · 10 companies
Healthcare provider profile · identity verified
Shoaib A Hashmi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BALTIMORE, MD · NPI 1821191412
Verified facts
What the public records show
CMS Open Payments records show Shoaib A Hashmi, MD received $588.99 in general payments during 2025 across 17 reported records.
SI-BONE, INC. accounted for 42.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Isentress by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 612 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $247.88 | 42.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.36 | 14.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.98 | 8.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $50.84 | 8.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.03 | 8.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.63 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.23 | 4.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.13 | 3.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $16.06 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $391.26 | 15 |
| Travel and Lodging | $178.88 | 1 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IFUSE IMPLANT SYSTEM Normalized: ifuse implant system |
Device | SI-BONE, INC. | $247.88 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $84.36 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $50.84 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.03 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 154 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 19 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
155 | 21 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
612 | 89 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 973 | 221 |
| Eliquis | Apixaban | 612 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 467 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 76 |
| Gabapentin | Gabapentin | 367 | 87 |
| Furosemide | Furosemide | 360 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 284 | 57 |
| Lisinopril | Lisinopril | 275 | 62 |
| Mirtazapine | Mirtazapine | 273 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 261 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 71 |
| Losartan Potassium | Losartan Potassium | 243 | 65 |
| Potassium Chloride | Potassium Chloride | 219 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 211 | 57 |
| Metformin Hcl | Metformin Hcl | 201 | 55 |
| Omeprazole | Omeprazole | 198 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 167 | 41 |
| Sertraline Hcl | Sertraline Hcl | 166 | 35 |
| Nifedipine Er | Nifedipine | 165 | 40 |
| Levetiracetam | Levetiracetam | 163 | 25 |
| Baclofen | Baclofen | 160 | 21 |
| Carvedilol | Carvedilol | 158 | 35 |
| Trulicity | Dulaglutide | 155 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 32 |
| Jardiance | Empagliflozin | 154 | 19 |
| Latanoprost | Latanoprost | 136 | 29 |
| Trazodone Hcl | Trazodone Hcl | 125 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 29 |
| Divalproex Sodium | Divalproex Sodium | 111 | 20 |
| Nystatin | Nystatin | 110 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 23 |
| Donepezil Hcl | Donepezil Hcl | 104 | 19 |
| Warfarin Sodium | Warfarin Sodium | 99 | 13 |
| Finasteride | Finasteride | 97 | 16 |
| Alendronate Sodium | Alendronate Sodium | 92 | 18 |
| Lactulose | Lactulose | 92 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 23 |
| Spironolactone | Spironolactone | 88 | 21 |
| Risperidone | Risperidone | 85 | 12 |
| Famotidine | Famotidine | 84 | 27 |
| Incruse Ellipta | Umeclidinium Bromide | 81 | suppressed |
| Tradjenta | Linagliptin | 81 | suppressed |
| Allopurinol | Allopurinol | 80 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 80 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 40 |
| Prednisone | Prednisone | 79 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 78 | 28 |
| Buspirone Hcl | Buspirone Hcl | 73 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | suppressed |
| Olanzapine | Olanzapine | 66 | 17 |
| Entresto | Sacubitril/Valsartan | 65 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 65 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | suppressed |
| Simvastatin | Simvastatin | 58 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 56 | 14 |
| Memantine Hcl | Memantine Hcl | 56 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 54 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Meloxicam | Meloxicam | 45 | 12 |
| Torsemide | Torsemide | 45 | 13 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | 11 |
| Enulose | Lactulose | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 20 |
| Metformin Hcl Er | Metformin Hcl | 41 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 39 | 19 |
| Gemtesa | Vibegron | 38 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 37 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 11 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 15 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 29 | suppressed |
| Fluorometholone | Fluorometholone | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | 16 |
| Novolog Flexpen | Insulin Aspart | 28 | 11 |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 12 |
| Rasagiline Mesylate | Rasagiline Mesylate | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | 13 |
| Bumetanide | Bumetanide | 24 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 24 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Restasis | Cyclosporine | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Nyamyc | Nystatin | 21 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 12 |
| Oxycontin | Oxycodone Hcl | 20 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 18 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 17 | 12 |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 16 | 12 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 15 | 13 |
| Valsartan | Valsartan | 15 | suppressed |
| Abilify Maintena | Aripiprazole | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Abacavir | Abacavir Sulfate | 12 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $588.99 · 17 records | SI-BONE, INC. | CAPVAXIVE, Cologuard Collection Kit, FARXIGA, IFUSE IMPLANT SYSTEM, JARDIANCE, Kerendia, MOUNJARO, VYNDAQEL, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error